BMY depends on Reblozyl, Opdualag and Breyanzi to offset revenue hits from generics and Medicare Part D impacts.

And Cobenfy's approval comes after two other recent setbacks in the late-stage schizophrenia pipeline; namely, the FDA’s rejection of Minerva Neurosciences’ application for roluperidone and ...

Cobenfy: A Key Growth Driver One of the most significant developments for Bristol-Myers Squibb has been the launch and performance of Cobenfy, its new drug for schizophrenia.

A top official at the Food and Drug Administration recently overruled government scientists on the availability of two ...

The US Food and Drug Administration’s top vaccine official overrode agency experts in May to recommend against the broad use ...

FDA vaccines chief Vinay Prasad limited broader use of COVID vaccines, citing reduced risk and data concerns. Read more here.

Regeneron Pharmaceuticals has won FDA accelerated approval of its Lynozyfic treatment for certain patients with the blood ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Merck (MRK) stock in focus as its lung disease drug Winrevair gains FDA priority review for a label update based on Phase 3 ...